Table 1.
CSCs markers in other solid tumors.
| Type of cancer | CSCs Markers | References |
|---|---|---|
| Head and neck squamous cell carcinoma | ALDH1, BMI1, c-MET, CD44, CD133 | (155–159) |
| Lung cancer | ALDH1A1, ABCG2, BMI1, CD44, CD133, CD87, CD90, CD166, EpCAM, NANOG, NUCLEOSTEMIN, OCT4, PODXL-1, SOX2 | (117, 160–163) |
| Esophageal carcinoma | ALDH1, ABCG2, CD13, CD44, CD90, CD271, INTEGRIN7, ICAM1, LGR5, SOX9 | (164) |
| Gastric cancer | BMI1, CD44, CD54, CD71, CD90, CD133, CD166, LGR5, MUSASHI-1, OCT4, SOX2 | (165) |
| Hepatocellular carcinoma | CD13, CD24, CD34, CD90, CD133, EpCAM, OV-6, SOX9, SOX12 | (166–169) |
| Pancreatic cancer | ALDH1, c-MET, CD24, CD44, CD133, CXCR4, DCLK1, EpCAM, Lgr5 | (170) |
| Colon cancer | ALDH1, CD26, CD29, CD44S, CD166, CXCR4 | (171, 172) |
| Prostate cancer | ALDH7A1, ATXN1, CD24, CD44, PTEN, CD133, GATA3, KLF4, MYC, NKX3-1, TACSTD2, TNFSF11, TNFRSF11B | (50, 52, 173) |
| Ovarian cancer | ALDH1A1, c-MYC, CD24, CD44, CD117, CD133, CD243, CD338, EpCAM, IL-17R, LIN28, NANOG, OCT4, ROR1, SOX2 | (49, 174–180) |
Most stemness markers are the same but a universal signature is still lacking.